Animal Drug Compounding Market Analysis

Animal Drug Compounding Market Analysis

To get key market trends

  Download Free Sample

Based on the animal type, the market is categorized as companion animals and livestock animals. The companion animals segment is set to lead the market, accounting for the largest revenue of USD 1.5 billion in 2023, anticipating its dominance throughout the forecast period.
 

• The companion animal segment dominance was asserted to the increasing number of pets and their growing healthcare needs.
   
• The rise in pet ownership and increased awareness of pet health tends to significantly propel the demand for personalized medications tailored to the specific health conditions of dogs, cats, and other pets.
   
• In addition, compounded drugs are often required to address unique dosage requirements and formulations not available in standard pharmaceuticals. The segment's expansion is driven by pet owners' willingness to invest in customized treatments for their pets, leading to substantial growth in the market.
   

Based on drug type, the animal drug compounding market is classified into anti-infective agents, anti-inflammatory agents, hormones & substitutes, CNS agents, and other drug types. The CNS agents segment holds the largest market share of 34.2% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• Veterinarians are increasingly turning to CNS agents to address a spectrum of neurological conditions in pets, ranging from seizures and behavioral changes to blindness.
   
• This class of drugs, spanning anticonvulsants, tranquilizers, and sedatives, targets health issues that conventional pharmaceuticals often struggle to address.
   
• Thus, with a growing appreciation among veterinarians for the efficacy of these specialized medications, the demand for CNS agents is on a steady ascent, cementing their dominance in the market.
   

Based on the dosage form, the animal drug compounding market is segmented into oral, topical, injectable, and other dosage forms. The oral segment leads the market, holding the largest revenue share in 2023, and is expected to maintain its dominance with a projected CAGR of 8.1% during the analysis period. The oral segment is further categorized into tablets, capsules, liquid, and other oral dosage forms.
 

• Oral medications are generally more palatable and can be easily customized to suit individual animal needs, enhancing compliance.
   
• This method is particularly favored for companion animals, as it minimizes stress during administration and allows for flexible dosage adjustments.
   
• In addition, the convenience of administering flavored formulations in food further drives the demand for oral compounded medications, solidifying their position as the leading segment in the market. This trend reflects the growing focus on personalized veterinary care.
   

Based on the distribution channel, the animal drug compounding market is segmented into veterinary hospitals pharmacies, compounding pharmacies, and other distribution channels. The compounding pharmacies segment holds the largest revenue share and is projected to reach 53.6% by 2032.
 

• Compounding pharmacies excel in tailoring medications to suit distinct veterinary requirements. They focus on creating customized formulations, bridging gaps left by standard-produced drugs, especially for rare animal diseases.
   
• In addition, to the high preference by the pet owners for tailored treatments, compounding pharmacies are pivotal in offering solutions, such as flavored oral medications and unconventional dosage forms.
   
• This increasing preference indicates an increased acceptance of personalized veterinary care, cementing the significance of compounding pharmacies in the sector.
   

U.S. dominated the North American animal drug compounding market accounting for USD 1.3 billion in 2023 and is anticipated to show considerable growth over the analysis period.
 

• High pet ownership rates and substantial R&D investments propel the U.S. market. The country witness’s significant veterinary healthcare spending. For instance, according to the American Pet Products Association in 2022, pet owners spent USD 31.5 billion on supplies, live animals, and medicine, and a staggering USD 35.9 billion on veterinary care and products. This underscores the escalating focus on pet healthcare. With an increased emphasis on veterinary care, pet owners are increasingly seeking tailored treatment options, fueling the demand for animal drug compounding.
   
• Additionally, the U.S. boasts a stringent regulatory landscape, bolstered by FDA guidelines. This, in conjunction with a plethora of veterinary clinics and hospitals, and a growing trend towards personalized animal care, further propels the market's expansion.
   

Germany exhibited a high growth potential in the European animal drug compounding market.
 

• Germany's prominence is exemplified by its advanced veterinary healthcare system and strong regulatory environment.
   
• The country’s well-established veterinary infrastructure supports a high demand for customized medication solutions, driven by its large pet and livestock population.
   
• With increasing investments in veterinary care and a growing focus on personalized treatments, Germany remains a key player in the European market.
   

The Asia Pacific animal drug compounding market is poised for rapid growth with a CAGR of 8.9% during the forecast period.
 

• Increasing pet ownership, a surge in awareness regarding advanced veterinary treatments, and rising expenditure on animal healthcare are driving growth in the region.
   
• The region's bolstered animal healthcare infrastructure, alongside increased investments in veterinary services, is fostering the growth of compounding pharmacies.
   
• Moreover, with ongoing advancements in veterinary medicine and a notable rise in chronic animal diseases, the market is witnessing further expansion.
   
• Thus, the aforementioned factors are expected to fuel the market growth in the region.